HCPCS Level II › Q

HCPCS Level II codes starting with Q

644 codes, page 7 of 7. Every code ever valid for billing is listed, including those now retired.

CodeDescriptionStatus
Q9954 Oral magnetic resonance contrast agent, per 100 ml Valid
Q9955 Injection, perflexane lipid microspheres, per ml Valid
Q9956 Injection, octafluoropropane microspheres, per ml Valid
Q9957 Injection, perflutren lipid microspheres, per ml Valid
Q9958 High osmolar contrast material, up to 149 mg/ml iodine concentration, per ml Valid
Q9959 High osmolar contrast material, 150-199 mg/ml iodine concentration, per ml Valid
Q9960 High osmolar contrast material, 200-249 mg/ml iodine concentration, per ml Valid
Q9961 High osmolar contrast material, 250-299 mg/ml iodine concentration, per ml Valid
Q9962 High osmolar contrast material, 300-349 mg/ml iodine concentration, per ml Valid
Q9963 High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml Valid
Q9964 High osmolar contrast material, 400 or greater mg/ml iodine concentration, per ml Valid
Q9965 Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml Valid
Q9966 Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml Valid
Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Valid
Q9968 Injection, non-radioactive, non-contrast, visualization adjunct (e.g., methylene blue, isosulfan blue), 1 mg Valid
Q9969 Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose through FY2026 Terminated
Q9970 Injection, ferric carboxymaltose, 1mg through FY2026 Terminated
Q9972 Injection, epoetin beta, 1 microgram, (for esrd on dialysis) through FY2026 Terminated
Q9973 Injection, epoetin beta, 1 microgram, (non-esrd use) through FY2026 Terminated
Q9974 Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg through FY2026 Terminated
Q9975 Injection, factor viii fc fusion protein (recombinant), per iu through FY2026 Terminated
Q9976 Injection, ferric pyrophosphate citrate solution, 0.1 mg of iron through FY2026 Terminated
Q9977 Compounded drug, not otherwise classified through FY2026 Terminated
Q9978 Netupitant 300 mg and palonosetron 0.5 mg through FY2026 Terminated
Q9979 Injection, alemtuzumab, 1 mg through FY2026 Terminated
Q9980 Hyaluronan or derivative, genvisc 850, for intra-articular injection, 1 mg through FY2026 Terminated
Q9981 Rolapitant, oral, 1 mg through FY2026 Terminated
Q9982 Flutemetamol f18, diagnostic, per study dose, up to 5 millicuries Valid
Q9983 Florbetaben f18, diagnostic, per study dose, up to 8.1 millicuries Valid
Q9984 Levonorgestrel-releasing intrauterine contraceptive system (kyleena), 19.5 mg through FY2026 Terminated
Q9985 Injection, hydroxyprogesterone caproate, not otherwise specified, 10 mg through FY2026 Terminated
Q9986 Injection, hydroxyprogesterone caproate, (makena), 10 mg through FY2026 Terminated
Q9987 Pathogen(s) test for platelets through FY2026 Terminated
Q9988 Platelets, pheresis, pathogen-reduced, each unit through FY2026 Terminated
Q9989 Ustekinumab, for intravenous injection, 1 mg through FY2026 Terminated
Q9991 Injection, buprenorphine extended-release (sublocade), less than or equal to 100 mg Valid
Q9992 Injection, buprenorphine extended-release (sublocade), greater than 100 mg Valid
Q9993 Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg through FY2026 Terminated
Q9994 In-line cartridge containing digestive enzyme(s) for enteral feeding, each through FY2026 Terminated
Q9995 Injection, emicizumab-kxwh, 0.5 mg through FY2026 Terminated
Q9996 Injection, ustekinumab-ttwe (pyzchiva), subcutaneous, 1 mg Valid
Q9997 Injection, ustekinumab-ttwe (pyzchiva), intravenous, 1 mg Valid
Q9998 Injection, ustekinumab-aekn (selarsdi), biosimilar, 1 mg Valid
Q9999 Injection, ustekinumab-aauz (otulfi), biosimilar, 1 mg Valid
Page 7 of 7